Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRD-1003
- Development stage
- Preclinical
- Lead developer
- Medera Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SRD-1003 is an investigational oral small molecule therapeutic being developed by Medera Group for the treatment of Duchenne cardiomyopathy. Duchenne cardiomyopathy is a progressive form of heart disease that occurs in patients with Duchenne muscular dystrophy (DMD) due to the absence of the protein dystrophin, leading to myocardial fibrosis and heart failure. As of 2024, SRD-1003 is in the preclinical stage of development. The specific molecular target and mechanism of action have not been publicly disclosed by the sponsor, but the asset is part of Medera's pipeline focused on addressing unmet needs in cardiac medicine.
Beyond the preview
Go deeper on SRD-1003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRD-1003.